Yeda Research and Develpment & Co. Ltd

Tsvee Lapidot

Orit Kollet

Alexander Kalinkovich

Michel Revel

Matityahu Fridkin

Judith Chebath

Amnon Peled

Menachem Rubinstein

Joy Kahn

Asaf Spiegel

Shoham Shivtiel

Sigal Tavor

Isabelle Petit

The invention is directed to &#x3b2;-defensin-derived peptides and their use in modulating the activity of hematopoietic cells, particularly hematopoietic stem cells and progenitor cells. Specifically, the invention provides compositions and methods useful for promoting mobilization and transplantation of hematopoietic stem cells and progenitor cells. The invention further provides compositions and methods useful in the treatment of cancer.

Short beta-defensin-derived peptides

The invention is directed to beta-defensin-derived peptides and their use in modulating the activity of hematopoietic cells and other CXCR4-expressing cells. Specifically, the invention provides compositions and methods useful in the treatment of cancer. The invention further provides compositions and methods useful for promoting mobilization and transplantation of hematopoietic stem cells and progenitor cells.

The present invention relates to stem cells suitable for transplantation and to methods for their preparation.

Stem cells suitable for transplantation, their preparation and pharmaceutical compositions comprising them

The present invention relates to stem cells which exhibit increased sensitivity to a chemoattractant and, more particularly, to methods of generating and using them such as in clinical applications involving stem cell transplantation.

Stem cells having increased sensitivity to SDF-1 and methods of generating and using same

The invention relates to receptors of catecholamines and their role in stem cell development and function.

Catecholamine receptor modulation

Stem cells having increased sensitivity to a chemoattractant and methods of generating and using same

Chimeric proteins constructed from the fusion of the naturally occurring form of the soluble IL-6 receptor and IL-6 which are useful for treatment of cancer and liver disorders, enhancement of bone marrow transplantation, and treatment of other IL-6 related conditions are provided.

Nucleic acids encoding chimeric interleukin-6 soluble receptor/ligand protein, analogs thereof and uses thereof

Chimeric interleukin-6 soluble receptor/ligand proteins

Cell compositions consisting essentially of mammalian hematopoietic CXCR4stem and progenitor capable to migrate in response to stromal-derived factor 1 (SDF-1) and/or capable to adhere to stromal cells in response to an adhesion-inducing agent, are provided for clinical transplantation. Hematopoietic CXCR4stem and progenitor cells can be converted into CXCR4cells by stimulation with a suitable agent. The composition consists preferably of human CD38CXCR4cells.

Growing community of inventors

Ness Ziona, Israel

Tsvee Lapidot